ManagedCareCGM.com Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy

Learn About:

• New HEDIS measures for diabetes care and the role of CGM in providing key metrics for reporting
• Improving health equity with glucose management indicator (GMI)
• Using CGM to optimize outcomes in patients taking GLP-1 agonists
• Current best practices in CGM coverage and access among managed care organizations

Expert Faculty Presenters

Sean Chitwood, PharmD, MBA Clinical Pharmacist, Medicare Stars & Clinical Quality Optum Rx Click here for biography Timothy Gilbert, MD Clinical Endocrinologist Imperial Health Click here for biography Fred Goldstein Moderator Accountable Health, LLC Click here for biography Maureen Hennessey, PhD, CPCC, CPHQ SVP, Director of Value Transformation PRECISIONValue Click here for biography Susan Wescott, RPh, MBA Senior Director of Pharmacy Managed Care Mayo Clinic Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Backed by a growing body of clinical evidence and expert recommendations, the role of continuous glucose monitoring (CGM) in managed care has expanded rapidly in recent years. In addition to improving glycemic control and reducing hypoglycemic risk, CGM has demonstrated the potential to enhance patient engagement and self-management with associated reductions in resource utilization and medication use. As managed care professionals remain mindful of evolving quality measures and a wide array of treatment options, CGM represents a complimentary intervention for integration in comprehensive programming. This symposium will feature a PayerTalkCE format with the faculty discussing the latest trends and opportunities for CGM in high-quality, cost-effective diabetes disease management.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
• Describe the synergistic impact of CGM and GLP-1 agonists
• Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-24-143-L01-P
Activity Type: Knowledge-based

Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.
Please note: Registration for AMCP 2024 is NOT required to attend this symposium.